Meridian Bioscience Expands Production Capacity with Support from NIH, JobsOhio, and the Village of Newtown February 03, 2021 10:30 ET | Source: Meridian Bioscience Inc. Meridian Bioscience Inc. Cincinnati, Ohio, UNITED STATES CINCINNATI, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it will increase production capacity of the company's SARS-CoV-2 molecular diagnostic test on its Revogene ® platform after receiving a $5.5M award from the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADx SM) initiative and an additional grant from JobsOhio. The funding will help Meridian expand production of Revogene